Jiangsu Hansoh Pharmaceutical Co., Ltd.

This early-stage study tests a new drug called HS-10587 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 362 participants who have tried …

This study tests an investigational injection called HS-20094 in people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. About 204 adults will receive either the drug or a placebo to see if it safely lowers blood sugar levels over 44 to 52…

This early-stage study tests a new drug, HS-10541, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tu…

This early-phase study tests a new drug combination (HS-10504 plus other therapies) in 400 people with advanced non-small cell lung cancer that has worsened after prior treatment. The goal is to find safe and effective doses and to measure how well the treatment shrinks tumors. P…

This study tests a new drug called HS-10542 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. About 90 adults will receive either the drug or a placebo to see if it safely reduces protein in the urine, a sign of kidney damage. The goal is to contr…

This early-stage study tests a new tablet called HS-10522 in healthy Chinese adults and those with mild hypertension. The main goal is to check safety and how the drug moves through the body. 88 participants will receive either the drug or a placebo to compare side effects and dr…

This study tests a new drug called HS-10566 in people with high-risk bladder cancer that hasn't spread into the muscle wall. Participants are those who cannot have or choose not to have their bladder removed. The study has two phases: first, finding the best dose, and second, che…

This study tests a new medicine called HS-10390 in 182 adults with chronic kidney disease. The goal is to see if it can lower protein levels in urine, a sign of kidney damage, better than standard care. Participants must already be on stable blood pressure medication and have mod…

This study tests a new drug called HS-10506 to help people with insomnia fall asleep faster and stay asleep longer. About 732 Chinese adults with insomnia will receive either the drug or a placebo for up to 84 days. The main goal is to see if the drug improves sleep quality measu…

This early-stage study tests whether a single injection of HS-20136-2 is safe and tolerable in healthy adults aged 18-65. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor for side effects and how the drug moves through t…

This early-stage study looks at how a common antifungal drug (itraconazole) changes the way the body handles an experimental drug called HS-10506. It involves 20 healthy Chinese adults aged 18-45. The goal is to measure drug levels in the blood, not to treat any disease.

This early-stage study tests the safety of a new drug called HS-20152 in 32 healthy adults aged 18 to 64. The drug targets the complement system, part of the body's immune response. Researchers will monitor for side effects and measure how the drug moves through the body. This st…